Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial

Authors: Gerd R Burmester, Frank Buttgereit, Corrado Bernasconi, José María Álvaro‐Gracia, Nidia Castro, Maxime Dougados, Cem Gabay, J.M. van Laar, Jan Michael Nebesky, Attila Pethoe-Schramm, Carlo Salvarani, Marc Y. Donath, Markus R. John, Arnaud Constantin, Jacques Éric Gottenberg, Sylvie Loiseau-Pérès, Minh Nguyen, Thierry Schaeverbeke, Rieke H.-E. Alten, C. Amberger, W Biewer, Konrad Boche, Gerd Ruediger Burmester, Andreas K. Engel, Martin Feuchtenberger, Martin Fleck, Georg Gauler, Bernhard Heilig, M. Höhle, Christof Iking‐Konert, Peter Kästner, David M. Kofler, Klaus Krueger, C Kühne, Reiner Kurthen, Hendrik Schulze‐Koops, Holger Schwenke, Maren Sieburg, Christof Specker, Hans‐Peter Tony, Siegfried Wassenberg, Jörg Wendler, Roberto Caporali, Oscar Massimiliano Epis, Roberto Caporali, Carlo Salvarani, A. A. Dubikov, R. G. Kamalova, М. А. Королев, Mazurov Vi, Ekaterina Puntus, Nemanja Damjanov, Tatjana Ilić, M. Lazarevic, Saša Milenković, Milan Petronijević, Cem Gabay, E. Bouajina, Mohamed Elleuch, E. Bouajina, Mohamed Elleuch - The Lancet 2020 cited by 125